Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperprolactinemia in systemic lupus erythematosus?

B Ostendorf1, R Fischer, R Santen

  • 1Center of Rheumatology, Heinrich-Heine-University of Düsseldorf, Germany.

Scandinavian Journal of Rheumatology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of systemic lupus erythematosus-Including secondary antiphospholipid syndrome, fertility and pregnancy : S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version: 1.2].

Zeitschrift fur Rheumatologie·2025
Same author

[Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].

Zeitschrift fur Rheumatologie·2024
Same author

[Position paper of the German Society of Rheumatology e.V. (DGRh) regarding the situation of advanced training in the discipline of rheumatology in Germany].

Zeitschrift fur Rheumatologie·2023
Same author

[Identification of rheumatological health apps in the Apple app store applying the "semiautomatic retrospective app store analysis" method : A longitudinal observation].

Zeitschrift fur Rheumatologie·2021
Same author

The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany.

Rheumatology (Oxford, England)·2021
Same author

[Vaccination against SARS-CoV-2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients].

Zeitschrift fur Rheumatologie·2021

Hyperprolactinemia (HPRL) is not common in systemic lupus erythematosus (SLE). Prolactin (PRL) levels did not correlate with SLE disease activity in this study.

Area of Science:

  • Endocrinology
  • Rheumatology
  • Immunology

Background:

  • Hyperprolactinemia (HPRL) is a condition of elevated prolactin (PRL) levels.
  • Previous studies suggested a potential link between HPRL and systemic lupus erythematosus (SLE).
  • The role of PRL as a marker for SLE disease activity requires further investigation.

Purpose of the Study:

  • To determine the prevalence of HPRL in patients with SLE.
  • To evaluate the association between PRL levels and SLE disease activity.
  • To assess PRL as a potential biomarker in SLE management.

Main Methods:

  • A cohort of 182 patients diagnosed with SLE was studied.
  • Basal serum prolactin (PRL) levels were measured in all participants.
  • Clinical data, including disease activity indices, serological markers, and medications, were analyzed.

Related Experiment Videos

Main Results:

  • Normoprolactinemia was observed in 98% of SLE patients (n=178).
  • Mildly elevated PRL levels were found in only four patients.
  • No significant association was found between PRL levels and SLE disease activity or sero-activity.

Conclusions:

  • Hyperprolactinemia is not prevalent in the studied SLE cohort.
  • Prolactin levels do not appear to be associated with systemic lupus erythematosus disease activity.
  • These findings contrast with some previous research, suggesting PRL is not a reliable disease marker in SLE.